Ketolides

04/01/1999 - "The increased activity of ketolides against gram-positive bacteria suggests that further study of these agents for possible efficacy against infections caused by these bacteria is warranted."
08/15/2006 - "The in vivo efficacy of several C(12) ethyl ketolides was demonstrated in a mouse infection model with Streptococcus pneumoniae as pathogen."
04/01/2003 - "Telithromycin is the first of a new class of antibacterials, the ketolides, which have been developed specifically to provide effective treatment for these infections. "
09/01/2017 - "Fluoroquinolones and ketolides are among the drugs of choice for the treatment of Haemophilus parainfluenzae infections. "
12/01/2005 - "Population mathematical modeling and Monte Carlo simulation have shown that the ability of macrolides, azalides, and ketolides to concentrate at the infection site has a considerable effect on microbial activity. "

01/01/2009 - "Thus the pharmacokinetics of ketolides may help to explain their good activity against a wide range of respiratory tract infections, although pharmacokinetic/pharmacodynamic calculations based on plasma pharmacokinetics would indicate only minor activity against pathogens except streptococci. "
12/10/2009 - "Discovery of azetidinyl ketolides for the treatment of susceptible and multidrug resistant community-acquired respiratory tract infections."
02/01/2008 - "Ketolides: pharmacological profile and rational positioning in the treatment of respiratory tract infections."
05/01/2005 - "Ketolides in the treatment of community-acquired respiratory tract infections: A review."
06/01/2004 - "Clinical efficacy of ketolides in the treatment of respiratory tract infections."

01/01/2004 - "Results of a number of clinical trials investigating 5-day therapy with oral cephalosporins, new quinolones or ketolides in acute (presumed) bacterial sinusitis in comparison with traditional 10-day treatment courses have been published demonstrating equivalent efficacy of 5-day and 10-day regimens. "

03/01/2005 - "Ketolides: new antimicrobials for community-acquired pneumonia."
02/01/2008 - "Combined with an advantageous pharmacokinetic profile (good oral bioavailability and penetration in the respiratory tract tissues and fluids; prolonged half-life allowing for once-a-day administration), these antimicrobial properties make ketolides an attractive alternative for the treatment of severe respiratory tract infections such as pneumonia in areas with significant resistance to conventional macrolides. "
07/01/2009 - "To compare the probability of target attainment (PTA) for macrolides and ketolides against penicillin-susceptible, intermediate, and resistant Streptococcus pneumoniae in both serum and epithelial lining fluid (ELF) of patients with community-acquired pneumonia (CAP). "
11/01/2006 - "Macrolides, fluoroquinolones, doxycycline, and ketolides show a good intrinsic activity against intracellular pathogens which are responsible for a variable percentage of community-acquired pneumonia (CAP). "
01/12/2006 - "As a rule, oral antibiotic treatment with aminopenicillin, macrolides, fluorchinolones, ketolides or cephalosporins is applied, but decision-taking is also codetermined, for example, by whether an atypical pneumonia is suspected, or whether additional risk factors need to be taken into account."

01/01/2003 - "New families of antibiotics as the ketolides or the oxazolidinones appear to be effective in the treatment of streptococcal infections, but it seems that only a policy of control of the consumption of antibiotics could globally decrease the occurrence of resistance."